<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Hcw Biologics Inc — News on 6ix</title>
<link>https://6ix.com/company/hcw-biologics-inc</link>
<description>Latest news and press releases for Hcw Biologics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 20:20:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/hcw-biologics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357cae78dffbe2df0f9dbc.webp</url>
<title>Hcw Biologics Inc</title>
<link>https://6ix.com/company/hcw-biologics-inc</link>
</image>
<item>
<title>HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-announces-adjournment-of-special-meeting-of-stockholders-due-to-lack-of-quorum</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-announces-adjournment-of-special-meeting-of-stockholders-due-to-lack-of-quorum</guid>
<pubDate>Thu, 30 Apr 2026 20:20:00 GMT</pubDate>
<description>MIRAMAR, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation today announced that the Company’s Special Meeting of Stockholders, held on April 27, 2026, at 10:00 a.m. Eastern Time (“Special Meeting”) was adjourned, without any business being conducted, due to lack of the required qu</description>
</item>
<item>
<title>HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-delivers-a-major-update-for-its-t-cell-engager-program-revealing-mechanism-of-action-and-validating-tissue-factor-as-target-for-treatment-of-solid-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-delivers-a-major-update-for-its-t-cell-engager-program-revealing-mechanism-of-action-and-validating-tissue-factor-as-target-for-treatment-of-solid-tumors</guid>
<pubDate>Mon, 27 Apr 2026 11:30:00 GMT</pubDate>
<description>Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities IND application expected to be filed in first half of 2027 to seek authorization for clinical study in patients with pancreatic cancer Poster presented at the American Association of Cancer Research Annual Meeting 2026 MIRAMAR, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a cl</description>
</item>
<item>
<title>HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-reports-fourth-quarter-2025-and-fiscal-year-2025-business-highlights-and-financial-results-2</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-reports-fourth-quarter-2025-and-fiscal-year-2025-business-highlights-and-financial-results-2</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-closes-exclusive-worldwide-license-for-hcw11-006-a-high-potential-fusion-immunotherapeutic</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-closes-exclusive-worldwide-license-for-hcw11-006-a-high-potential-fusion-immunotherapeutic</guid>
<pubDate>Tue, 17 Mar 2026 11:50:00 GMT</pubDate>
<description>Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee Initiation of Phase 1 clinical study in China by licensee expected in the first half of 2027 HCW Biologics has “free” option to reclaim the rights to the Americas territory MIRAMAR, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based commercial- and clinical-stage</description>
</item>
<item>
<title>HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-announces-positive-research-results-for-car-t-cell-therapy-manufactured-utilizing-its-commercial-ready-proprietary-compound-hcw9206-published-in-science-advances</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-announces-positive-research-results-for-car-t-cell-therapy-manufactured-utilizing-its-commercial-ready-proprietary-compound-hcw9206-published-in-science-advances</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In</description>
</item>
<item>
<title>HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-regains-compliance-with-all-continued-listing-rules-for-nasdaq-per-nasdaq-determination-letter</guid>
<pubDate>Mon, 02 Mar 2026 13:00:00 GMT</pubDate>
<description>MIRAMAR, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and disease, today reported that, on February 26, 2026, the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq” or the “Exchange”) found that the Company regained compliance with all co</description>
</item>
<item>
<title>HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-announces-pricing-1-025000560</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-announces-pricing-1-025000560</guid>
<pubDate>Wed, 18 Feb 2026 02:50:00 GMT</pubDate>
<description>MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chronic inflammation and disease, today announced the pricing of its follow-on offering of an aggregate of 2,477,292 units at a purchase price of $0.6055 per unit priced at-the-market under Nasdaq rules. Each unit consists of on</description>
</item>
<item>
<title>HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-wy-biotech-announce-133000604</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-wy-biotech-announce-133000604</guid>
<pubDate>Fri, 13 Feb 2026 13:30:00 GMT</pubDate>
<description>HCW Biologics receiving cash fee and co-founder shares in Trimmunevalued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with HCW Biologics’ TRBC drug development platform Initiation of Phase 1 clinical study expected in the first half of 2027 HCW Biologics retains royalty-free option to reclaim the rights to the Americas territory MIRAMAR, Fla., Feb. 13, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics”) (NASDAQ</description>
</item>
<item>
<title>HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-enters-4-0-133000987</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-enters-4-0-133000987</guid>
<pubDate>Wed, 19 Nov 2025 13:30:00 GMT</pubDate>
<description>MIRAMAR, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link between chronic inflammation and disease, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on No</description>
</item>
<item>
<title>HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-announces-initiation-first-122500729</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-announces-initiation-first-122500729</guid>
<pubDate>Tue, 18 Nov 2025 12:25:00 GMT</pubDate>
<description>First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions of regulatory T cells to control excessive inflammation Gateway to development of a first-in-kind immunotherapeutic for autoimmune and pro-inflammatory diseases MIRAMAR, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage bi</description>
</item>
<item>
<title>HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-reports-third-quarter-214400773</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-reports-third-quarter-214400773</guid>
<pubDate>Fri, 14 Nov 2025 21:44:00 GMT</pubDate>
<description>MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2025. The Company anticipates dosing the first patient in a Phase 1 clinical study (NCT0704</description>
</item>
<item>
<title>HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-shares-latest-data-120000222</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-shares-latest-data-120000222</guid>
<pubDate>Mon, 10 Nov 2025 12:00:00 GMT</pubDate>
<description>HCW11-040 is a first-in-class pembrolizumab-based, tetra-valent immune checkpoint inhibitor designated as Company’s franchise immunotherapeutic for internal clinical developmentMIRAMAR, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseas</description>
</item>
<item>
<title>HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-presents-preclinical-data-120000102</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-presents-preclinical-data-120000102</guid>
<pubDate>Fri, 07 Nov 2025 12:00:00 GMT</pubDate>
<description>Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumorsMIRAMAR, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and</description>
</item>
<item>
<title>HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-inc-nasdaq-hcwb-130000605</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-inc-nasdaq-hcwb-130000605</guid>
<pubDate>Wed, 22 Oct 2025 13:00:00 GMT</pubDate>
<description>Watch the "What This Means" video here Featuring the Company’s pembrolizumab-based immune checkpoint inhibitor MIRAMAR, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that Peter Rhode, PhD, Chief Scientific Office</description>
</item>
<item>
<title>HCW Biologics to Participate in the 2025 Maxim Growth Summit</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-participate-2025-maxim-132500475</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-participate-2025-maxim-132500475</guid>
<pubDate>Thu, 16 Oct 2025 13:25:00 GMT</pubDate>
<description>MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, is pleased to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC. This prestigious event brings together industr</description>
</item>
<item>
<title>HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-scientists-present-three-131500889</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-scientists-present-three-131500889</guid>
<pubDate>Thu, 16 Oct 2025 13:15:00 GMT</pubDate>
<description>Company poster presentations will debut research data of three lead drug candidates constructed with Company’s novel TRBC platform technologyMIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, will present three posters to showcase the re</description>
</item>
<item>
<title>HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-inc-nasdaq-hcwb-124500109</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-inc-nasdaq-hcwb-124500109</guid>
<pubDate>Tue, 30 Sep 2025 12:45:00 GMT</pubDate>
<description>Watch the "What This Means" video here Featuring Company’s second-generation T-Cell Engager program and advantages over first-generation Company’s T-Cell Engager program has made improvements in manufacturability, preclinical safety profile, and ability to treat a wide spectrum of solid tumors MIRAMAR, Fla., Sept. 30, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and dev</description>
</item>
<item>
<title>HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-shareholder-wugen-congratulates-131500022</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-shareholder-wugen-congratulates-131500022</guid>
<pubDate>Thu, 18 Sep 2025 13:15:00 GMT</pubDate>
<description>Wugen closed a $115 million equity financing led by Fidelity Management & Research Company HCW Biologics holds a minority equity interest in Wugen MIRAMAR, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, congratulates Wugen, Inc.</description>
</item>
<item>
<title>HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-designates-one-proprietary-120000464</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-designates-one-proprietary-120000464</guid>
<pubDate>Tue, 16 Sep 2025 12:00:00 GMT</pubDate>
<description>Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid tumors Discovery of unique combination of cytokines in multi-functional fusion protein molecule that exhibits ability to expand TPEX cells without cytokine storm in preclinical studies Definitive data from preclinical studies shared at Scientific Seminar Series held at Nova Southeastern University on September 12, 2025, in Fort Lauderdale, Florida MIRAMAR,</description>
</item>
<item>
<title>HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program</title>
<link>https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-reports-positive-results-120000746</link>
<guid isPermaLink="true">https://6ix.com/company/hcw-biologics-inc/news/hcw-biologics-reports-positive-results-120000746</guid>
<pubDate>Tue, 09 Sep 2025 12:00:00 GMT</pubDate>
<description>HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated at a level significantly higher than the identified efficacious dose level Program has addressed key challenges for first generation T-cell engagers related to manufacturability, preclinical safety profile, and ability to treat a wide spectrum of solid tumors Program is positioned for a potential high value corporate partnership MIRAMAR, Fla., Sept. 09, 2</description>
</item>
</channel>
</rss>